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Abstract
Metagenomics, the analysis of the microbial genome, permits
scientists to understand the influences of external sources
including diet, metabolism and antibiotics on the human microbiome. Research has revealed the possibility of a core
symbiosis between humans and bacteria. The main role of
the human microbiome is to aid in digestion, but identified
ancillary roles include immunologic homeostasis and infection prevention. Quantifying the composition and variability
of the microbiome will help lead to future treatments or preventive strategies against unhealthy change. A variety of
methods may be used to define the microbiome, and 16S amplicon sequencing is primarily utilized today. Probiotics positively influence the microbiome by altering levels of proinflammatory and anti-inflammatory cytokines. Pharmacists
can provide a role in metagenomics by counseling patients
on the proper diet and probiotic consumption.
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Introduction
The microbiome has demonstrated stability over the course
of a lifetime.1 The gastrointestinal (GI) microbiome, composed of bacteria, archaea and viruses, can contain as many
as one hundred trillion species of flora and are typically analyzed through the use of fecal samples.2 Some of these microorganisms possess 150 times more genes than the typical
human.3 The microbiota varies from person to person, but
evidence suggests there are some commonalities.
Metagenomics is defined as the genomic analysis of microorganisms by direct extraction and cloning of deoxyribonucleic
acid (DNA) from an assemblage of microorganisms.4 Utilizing
metagenomics allows researchers and clinicians to define
genetic contents and attributes associated with the human
microbiome. By understanding the contents associated with
the microbiome, researchers can understand the impact that
metagenomics has when influenced by outside sources such
as diet and antibiotics as well as internal sources like metabolism.2
Methods of Quantifying Metagenomics
Recent methods of quantification use specific phylogenetic
marker genes, and are known as cultivation-independent
studies.5 Some studies have explored the degree of variability in the microbiome from person to person, the sequencing
and characteristics of the GI flora and the changes that occur
to the gut microbiota throughout life. Several important

48

methods have been developed for sequencing the genes from
the microscopic organisms of the gut.
One of these methods is known as the 16S RNA-encoding
gene (16S) and involves the comparison of a sample of gut
bacteria to bacterial sequencing databases. The 16S method
was used to determine that there are two main bacteria classifications within the gut, the bacteroidetes and the firmicutes, which account for 90 percent of the overall bacterial
population in the GI tract.3
Using a lower-error 16S amplicon sequencing method (LEASeq), researchers found that, in 37 adult subjects, more than
70 percent of the fecal bacteria were stable over the course
of a year. This means that, despite bacterial turnover, when a
bacterial cell died it was replaced by a similar-acting organism.1 Up to 60 percent of approximately 200 strains of sequenced gut bacteria was retained throughout a five-year
time period.
A 2013 study, as part of the Metagenomics of the Human Intestinal Tract (MetaHIT) project, analyzed stool samples
from 124 individuals in order to determine similarities and
differences between individuals.3 A total of 3.3 million nonredundant fecal microbial genes were sequenced using the
Illumina-based metagenomic method. The Illumina Genome
Analyzer method is able to sequence even more complex
communities of bacteria than the 16S. In this study, 576.6 GB
of genes were sequenced producing 200 times more data
than generated by any other study using rRNA sequencing
technology. This methodology found that 99.1 percent of the
genes sequenced were bacterial. In addition, it was determined that approximately 38 percent of the total bacterial
“gene pool” was common between individuals. This suggests
the existence of a “functional core” of microbes needed in
order to maintain proper functioning of the gastrointestinal
tract.
Understanding the makeup and genetic characteristics of the
microbiome is the first step toward determining the functions that these species carry out within the human body and
studying the ways in which to cultivate a healthy internal
microenvironment for these organisms to grow.
Role of the Microbiome
The microbiome plays an important role in the overall physiologic functioning of the GI tract, especially in digestion.
Some dietary compounds that the human body is unable to
digest are metabolized by bacteria in the gut, which is significant because certain indigestible compounds generate nutrients that are vital for physiologic function. 6 For example,
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humans are unable to digest xyloglucans, a fiber found in
most vegetables including lettuce and onions. Bacteroides
found in the gut metabolize these compounds into short
chain fatty acids (SCFAs) which are an energy source for the
intestinal mucosa. These SCFAs may have an additional role
in pathology of some diseases, but research is still unclear as
to what specific roles these metabolites may hold.7
Additional research indicates that some gut microbiota directly affect bioavailability, efficacy and toxicity of many oral
drugs due to a first-pass effect. After conducting a genomewide profile of xenobiotic metabolizing enzymes and respective metabolizing capabilities of various bacteria, 850 bacterial genera were identified that could metabolize one or
more xenobiotics.8 Researchers found that some of the gut
microbiota were able to affect expression levels of drugs examined for their metabolic pathways; however, the names
of the drugs were not otherwise clarified. Gut microbiota
acted similarly to other endogenous enzymes such as the
cytochrome P450 (CYP450) enzymes in metabolizing xenobiotics. Interestingly, researchers also found that certain
subgroups of the 850 bacterial genera (referred to as HV xenobiotic metabolizers or G3) were highly versatile in the gut
microbiota and could not only metabolize more varied types
of xenobiotics but also appeared to increase their growth in
correlation to increased doses of drugs. This may have future
applications in drug design because there may be ways to
predict patient response to different types of oral drugs
based on the makeup of their gut microbiome.

The gut microbiome has a role in immunological homeostasis
as well as inflammatory responses.9 Flora found within the
gut help remove harmful stimuli, such as pathogens, damaged cells or other irritants, from the gut in order to enhance
the healing process. It has been shown that altering the composition of the microbiome, or even removing parts of the
microbiome provokes type 2 immune responses and ultimately leads to allergic, infectious and inflammatory complications. For example, diets high in fat change the population
of the microbiome. This alters signaling to the brain, especially to satiety centers, which can ultimately lead to obesity
and inflammatory responses. Gut microbiota is a strong inducer of proinflammatory T helper 17 cells and regulatory T
cells in the intestine. This response leads to recruitment of
immune cells, such as macrophages, to remove causes of infection and other cells to promote tissue restoration. Cells in
the colon activate toll-like receptors in colonic mucosa to
achieve similar effects.
Furthermore, microbiota in the gut can help prevent infection.10 Research has measured the effect of restoring gut
microbiota to confer resistance against Clostridium difficile
(C. difficile). Since C. difficile is often contracted due to the
destruction of gut flora with broad-spectrum antibiotic use,
the theory was that adding certain types of gut flora could
decrease the incidence of C. difficile. One of the species of gut
microbiota found was Clostridium scindens which increased
levels of secondary bile acids deoxycholate (DCA) and
lithocolate (LCA) when introduced. Both DCA and LCA have

Drug Abuse
Infectious
Disease

been shown to inhibit C. difficile in a dose-dependent fashion.
This study has future clinical potential as it demonstrates
that certain species of the gut microbiota are essential to
combat and prevent diseases related to C. difficile.
In addition to impacting the healthy functioning of the gastrointestinal system, the microbiome has roles in disease,
inflammation and infection in other systems in the body. As
mentioned earlier, one function of bacteria is metabolism of
indigestible compounds in food. Microbes can metabolize
phosphatidylcholine into trimethylamine (TMAO).11 Trimethylamine can contribute to the development of atherosclerosis which is a factor in cardiovascular diseases (CVD). An
increase in plasma levels of TMAO has shown to increase the
risk of CVD in patients with pre-existing risk factors.12
The presence of Prevotella copri in the GI tract, as opposed to
typical bacteroides species, increases the risk of developing
rheumatoid arthritis.13 The proposed mechanism is that
P. copri may be a promoter of inflammation. This suggests
targeting the elimination of P. copri from the microbiome
may be an efficacious treatment for rheumatoid arthritis
(RA). Another pro-inflammatory bacteria found in the GI
tract is Fusobacterium nucleatum which may contribute to
tumor progression and metastasis in colon cancer. 14 F. nucleatum is an invasive species of bacteria that is not normally
found in the GI, but its presence has correlated with a higher
incidence of appendicitis, periodontitis and colorectal cancer.
It was found that the abundance of F. nucleatum was 415
times greater in colorectal tumors than in normal tissue.15
In contrast, while an increase in the amount of certain bacteria or presence of a bacteria in the gut may contribute to the
development of disease and inflammation, the lack of GI bacteria is a contributing factor to the development of obesity.16
This is evidence for the importance of health habits that both
promote the presence and growth of beneficial bacteria,
while limiting the overgrowth of strains that can be hazardous to health.
Causes of Changes to Microbiota
Multiple factors can change the microbiota including eating
habits, medications and sleep patterns. One study evaluated
adjusting obese patients’ normal diets to an individualized
very low energy diet that is high in protein, low in carbohydrates and low in fat. Using quantitative polymerase chain
reaction (qPCR) it was found that multiple populations of
bacteria had decreased including Clostridium leptum and
Lactobacillus. The Bacteroides population was found to have
increased using the same method.17 The fluorescent in situ
hybridization (FISH) method was also used in order to study
bacterial colonies. The bacterial counts found with FISH support that of qPCR while also looking at several other bacteria
species; none of which had significant changes in population.
The species of bacteria that did have significant changes are
common within the human microbiome.
Another study researched the effects of vegetarian diets
on the microbiome in comparison to an omnivore diet;
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Clostridium and butyrate-producing bacteria were found to
be increased in the omnivore diets.18 Both play a major role
in producing butyrate, one of the SCFAs used by GI endothelial cells as an energy source. It is still unknown how this decrease in butyrate-producing bacteria will affect the GI in
vegetarians, but butyrate is associated with anti-inflammatory properties, anticarcinogenic properties and decreased oxidative stress.19
Medications are also effectors of the GI microbiome. As previously discussed, antibiotics in particular are known to kill
natural gut bacteria. Consequently, the GI is left open to opportunistic infections. A study that evaluated the bacteria
that metabolize primary bile acids to secondary bile acids
found that first-line antibiotics decrease populations of these
bacteria. This causes a buildup of primary bile acids which
promotes the growth of C. difficile which then produces toxins that cause inflammation and diarrhea.20
While not often associated with its effects on the microbiome, sleep is also a major contributor to the overall balance
of the body. An animal study with mice has shown that disruptions in normal sleep patterns shift the prevalence of
multiple species of bacteria with a greater effect on mice on a
high fat, high sugar diet. It is also important to note that the
altered diets match those of “typical” Americans more closely
than the unaltered diets.21 Lactobacillus and bacteroides had
significant decreases of population in the mice with the altered diets. Large changes were also observed in half of the
40 species of bacteria on which the study focused.
It has also been shown that GI microbiota are important in
gene expression in GI endothelial cells. For example, expression of immune function in endothelial cells is dependent on
active vitamin D3.22 Vitamin D3 is activated by CYP27B1 enzyme which was decreased in mice that had an almost germfree environment.
Probiotics
The role of probiotics and their impact on metagenomics
have led researchers to investigate their potential medical
utility as an addition to traditional therapies. In one study
which focused on the treatment of Helicobacter pylori infection, one patient group was treated with traditional triple
antibiotic therapy while another additionally received probiotics (specifically Medilac-S©; Streptococcus faecium and
Bacillus subtilis) with the traditional treatment.23 The study
found that participants without the probiotic had altered
intestinal microbiomes. These results were determined from
an evaluation of metagenomic DNA extracted from the fecal
samples of all participants and an analysis from the Illumina
MiSeq system which generated whole metagenomic sequences from said samples. In the samples of the probiotic group,
there was a lower proportion of genes related to selenocompound metabolism, an increased number of genes related to
the catabolism of nucleotide sugars and an increase in proportional shift in functional gene families. The authors postulated these changes in intestinal microbiomes could lead to
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increased side effects including diarrhea and a higher chance
for antibiotic resistance.
Special populations of patients such as those with irritable
bowel disease (IBD) and relapsing ulcerative colitis (UC) may
benefit from regular probiotic use. Research has shown the
probiotic formulation VSL#3 has the potential to reduce the
symptoms of mild to moderate IBD, reduce a patient’s Ulcerative Colitis Disease Activity Index (UCDAI) score by nearly
50 percent by the sixth week of therapy and achieve a clinical
remission by the 12th week along with standard therapies
such as azathioprine or 6-mercaptopurine (p<0.001).24 In a
similar study, relapsing UC patients benefited with VSL#3.
Patients had a reduction of symptoms and induced remission
by the eighth week when combined with concomitant medication to treat UC. However, the study’s results did not
achieve statistical significance.25 Researchers believe some
attributed factor to be the cause for a decrease in gastrointestinal irritation and less alteration to the microbiome’s genome, although further studies are warranted to validate
these positive claims for probiotics.
Not only are microbiomes capable of being altered or protected by probiotics, but the proteins within an individual
can possibly be influenced by exposure to probiotics. In a
Finnish study that analyzed the fecal samples of 16 individuals, half received Lactobacillus rhamnosus GG for three
weeks (1,010 colony forming units per day) while the other
half received a placebo to determine the potential impact of
probiotics on an individual metaproteome or set of proteins.26 All proteomes were analyzed via mass spectrometry.
The investigators discovered that all participants shared a
similar set of proteins. About 10 percent of proteins within
all subjects’ metaproteomes were identical, establishing a
core ecosystem within the intestines. Most of these proteins
functioned to assist in carbohydrate transport, energy production, energy conversion, amino acid transport and metabolism. Other discoveries included a set of stable but varying
sets of proteins in each of the subjects. This means these proteins were different from patient to patient but remained
unchanged throughout the course of the study. Toward the
end of the study, researchers observed that the functionality
of the microbiome of healthy individuals of either group remains very similar yet does not imply similarity in the actual
activity of the microbiota of all individuals. The study did not
find noticeable changes within the metaproteome but noticed altered signaling in bacteria within the ileum. Results
from this study warrant further investigation to determine if
a significant benefit is established with probiotics, but presently the potential benefits outweigh the risks of taking probiotics.
The microbiome is subject to the consequences of human
aging. One consequence is the body becomes more prone to
infection and the microbiome grows weaker. Thus, researchers have focused on using a combination of prebiotics and
probiotics as a way to augment the microbiomes of the geriatric population. In one study, the prebiotics used were
bimuno galacto-oligosaccharides (B-GOS) and inulin while
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the probiotics used were Bifidobacterium bifidum, Lactobacillus acidophilus, and Bacillus coagulans.27 As a way of
avoiding confounding factors, all subjects in the study were
antibiotic free for at least six months and over the age of 60
years. Based on stool analyses throughout the study, researchers found that the combination of prebiotics and probiotics helped increase saccharolytic fermentation leading to
decreased inflammation of the GI. The prebiotics led to an
increase in the production and levels of the anti-inflammatory cytokine interleukin 10 (IL-10) and reduced levels of
the pro-inflammatory cytokine tumor necrosis factor alpha
(TNF-α). B.bifidum promoted flora growth throughout the GI
tract and, overall, both prebiotics and probiotics decreased
chance for infection and reduced the risk for disease.

Role of the Pharmacist
With growing knowledge about the gut microbiome, the
pharmacist’s role in counseling patients about different aspects of the microbiome and metagenomics becomes crucial.
Knowledge about the gut microbiota may help a pharmacist’s
understanding of commercially available probiotics and how
to best answer questions patients may present. The most
frequently used strains in probiotics are Lactobacillus and
Bifidobacterium.28 While there are no direct trials that compare the efficacy of commercially available probiotics, thus
making it difficult to determine the best probiotic, different
probiotic strains may confer beneficial effects to patients. For
example, a meta-analysis assessed whether probiotic use
could decrease the incidence of C. difficile associated diarrhea (CDAD) due to antibiotic use.29 After examining 23 randomized controlled trials, the authors concluded that when
probiotics are given with antibiotics, the risk of developing
CDAD decreased by about 64 percent with side effects including abdominal cramping, nausea, fever, soft stools, flatulence and taste disturbance. Overall, the authors determined
that short-use of probiotics would be beneficial in reducing
risk of CDAD in patients who are not immunocompromised
or severely debilitated. Counseling on potential side effects
such as gas and bloating is also important. Probiotics may be
able to help mitigate damage to the gastrointestinal tract that
can accompany antibiotic treatment. Recent advances in DNA
sequencing has allowed the ability to study microbial communities (such as those available in commercially available
probiotics) in their natural environments without needing to
isolate those communities or cultivate a specific species.30
This may offer a more convenient and thorough examination
of different probiotics that will help clinicians review the
benefits and drawbacks to certain products in order to best
fit each individual patient’s need.
Furthermore, pharmacists can also counsel patients on
avoiding certain types of food that may upset the gut microbiome. A study performed using E-probe Diagnostic Nucleic
acid Analysis (EDNA) identified harmful pathogens that
arose during major food outbreaks.4 A particular strain, E.
coli O157:H7, was highly associated with food poisoning as
well as hemorrhagic diarrhea. Being aware of different pathogens that may affect the flora of the gut can help educate
patients and avoid negative outcomes. Also, a different study

Drug Abuse
Infectious
Disease

measured the correlation between artificial sweeteners and
their effects on the gut.31 The investigators found the use of
artificial sweeteners was linked to an increased risk of glucose intolerance and seemed to be related to modulation of
the microbiota in both mice and humans. This stresses the
importance that the gastrointestinal microbiome has in other
disease states. By educating patients, pharmacists may be
able to decrease or prevent future development of chronic
disease states.
Finally, it is also important that the pharmacist can counsel
patients on food that will positively affect the microbiome.
Some metagenomic studies have been conducted on certain
foods containing bacteria that are commonly found in probiotics such as the Lactobacillus bacteria.32 This bacteria is
commonly found in cheese, fermented foods such as seafood
and yogurt, or in certain beverages. Pharmacists can educate
patients that consuming these foods in moderation may help
improve the overall health of their gut microbiome.
There are many ways a pharmacist can have a role when it
comes to the gut microbiome and metagenomics. A pharmacist can educate on the many probiotics available over the
counter and can counsel on different foods that can both positively and negatively impact the gut microbiota. Also, being
aware of the new technology of metagenomics will help enhance the understanding of the gut microbiome and what can
be done to further educate and improve the daily lives of patients.

Conclusion
Recent studies about the GI microbiome have revealed there
are many common species (mainly from the Bacteroidetes
phylum) that are near universal. This common core of bacteria is resistant to change and is relatively stable throughout a
person’s lifetime. In addition, gut bacteria functions to help
digest food, prevent infection, metabolize drugs and mediate
immune system responses but can also contribute to inflammatory diseases. Measures such as using a probiotic, avoiding artificial sweeteners and maintaining a stable sleep cycle
may ensure the health of the microbiota and promote overall
well-being.
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